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Introduction: Patients coinfected with human immunodeﬁciency virus (HIV) and hepatitis C virus (HCV) suffer from faster
progression of liver ﬁbrosis (LF) and have greater risk of worse clinical outcomes. We evaluated predictors and incidence of these
events in a large multicentre cohort.
Methods:We selected all HIV-infected patients starting a ﬁrst-line combination antiretroviral therapy (cART), with detectable HCV-
RNA, without exposure to interferon/ribavirin, with ≥2 ﬁbrosis-4 index (FIB-4) classiﬁcations before cART. Kaplan–Meier analysis was
used to estimate incidence of clinical events (AIDS, non-AIDS related, deaths) and LF progression (via transitions: from FIB-4 class 1
to 2 or 3, from class 2 to class 3, and worsening by 0.5 point). Multivariate Cox regression was used to assess predictors, baseline, or
time updated.
Results:One thousand four hundred thirty-three patients were selected. Overall, 745 clinical events occurred, with an incidence of
7.6% over 9811 person-year of follow-up (PYFU) and a median survival time of 9.36 years. Incidence of LF progression from FIB-4
class 1 to 2 or 3 was 12.4%, and from FIB-4 class 2 to 3 was 7%with a median survival time of 5.67 and 10.35 years, respectively. At
multivariate analyses, intravenous drug use and time-updated gamma-glutamyl transferase (gGT) were negative predictors for any
outcomes, either clinical or FIB-4 progression. Higher CD4+ T-cell protected from clinical events, and lower HIV-RNA and higher CD4
+ T-cell appeared to protect from FIB-4 transitions. Moreover, independently from the viro-immunological status, current FIB-4 class
3 predicted clinical events. Occurrence of AIDS and cardiovascular/kidney events were signiﬁcant predictors of 0.5 point worsening
and transitions of FIB-4, respectively. Prolonged exposure to nucleos(t)ide reverse transcriptase inhibitors (NRTI) was a negative
predictor for any outcomes.
Conclusion: Both clinical and LF progression in HIV/HCV-coinfected patients depend strongly on immune status. Intravenous
drug users and patients with high gGT (a possible proxy for alcohol abuse) are most-at-risk for both outcomes, as well those who had
prolonged exposures to the NRTI class. Therefore, these patients should be prioritized for the access to anti-HCV therapy and a test-ditor: Liang Shang.
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Focà et al. Medicine (2016) 95:29 Medicineand-treat strategy should be implemented for early initiation of cART. Possible beneﬁts of NRTI sparing regimens in HIV/HCV-
coinfected patients should be investigated.
Abbreviations: gGT= gamma-glutamyl transferase, ALT= alanine aminotransferase, AST= aspartate aminotransferase, cART=
combination antiretroviral therapy, CDC = Center for Diseases Control and prevention, CI = conﬁdence interval, FIB-4 = ﬁbrosis-4
index, HBsAg = hepatitis B surface antigen, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HCV-Ab = anti-HCV
antibodies, HIV = human immunodeﬁciency virus, HR = hazard ratio, IQR = interquartile range, LF = liver ﬁbrosis, NNRTI =
nonnucleoside reverse transcriptase inhibitors, NRTI = nucleos(t)ide reverse transcriptase inhibitors, PI = protease inhibitors, PI/r =
ritonavir boosted protease inhibitors, PYFU = person-year of follow-up.
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In human immunodeﬁciency virus (HIV)-infected patients,
chronic hepatitis C virus (HCV) infection is common due to
shared modes of transmission, and it is characterized by an
accelerated progression of liver ﬁbrosis (LF).[1,2] This can
potentially lead to cirrhosis, hepatocellular carcinoma and
decompensated liver disease, accounting for a substantial
morbidity and mortality in this population even in the
combination antiretroviral therapy (cART) era.[3–5] Consequent-
ly, all HIV-infected patients with HCV coinfection should be
treated for HCV, but in many countries, including Italy, only
those with a signiﬁcant degree of LF or comorbidities are
prioritized due to cost constraints.[6]
Staging of LF and evaluation of LF progression are crucial to
providing prognostic information and guiding physicians in
deciding priority and timing to start anti-HCV treatment.[7] Liver
biopsy is considered the gold standard for staging of LF.[7]
However, it is an invasive procedure and has limited patient
acceptability.[8] Moreover, results are affected by sampling errors
and inter/intraobserver variability,[9,10] and its use is unpractical
to assess the progression of LF over time, as biopsies would be
required repeatedly. For these reasons, several methods for
noninvasive assessment of LF have been proposed.[11,12] Some of
these methods, such as the ﬁbrosis-4 (FIB-4) index, are based on
serum biomarkers, reﬂect with acceptable accuracy the degree of
LF and are signiﬁcant predictors of hepatic decompensation and
liver-related deaths both in HIV mono-infected and in those with
positive HCV antibodies.[13–15]
However, comprehensive prognostic models for morbidity and
mortality in HIV-infected patients coinfected with HCV are
lacking or imperfect. First, it has not been assessed if, and to what
extent, HIV by itself and HIV-related complications (such as
AIDS and not AIDS events) impact LF progression, which in turn
may inﬂuence the risk of mortality. This hypothesis is based on a
previous study of our group in HIV-infected patients not
coinfected by HCV.[13] Indeed, HIV RNA control induced by
cART appeared to counteract LF progression, an observation
that has been conﬁrmed using different methods (e.g., transient
elastometry) in a patient group mainly composed by HIV mono-
infected individuals.[16] Therefore, HIV by itself may have a
direct effect on ﬁbrogenesis, and variables related with the HIV
natural history (such as HIV RNA, CD4+ T-cell count, and AIDS
events) may have a signiﬁcant effect in accelerating or predicting
LF progression in HIV/HCV-coinfected patients. Second, an
important limitation of the current prognostic models is that
patients with positive anti-HCV antibodies (HCV-Ab) are
selected, without consideration of HCV-RNA (in some cases,
patients have spontaneously eradicated HCV), and this may have
confounded risk estimates associated with other variables2tested. In conclusion, there is a need for more studies
conducted in HIV-infected patients with conﬁrmed HCV
coinfections (assessed through positive HCV-RNA) to explore
whether FIB-4 plays a role as a predictor of clinical evolution and
survival in relationship with HIV-related variables and occur-
rence of AIDS and non-AIDS-related events.
For the reasons above, we have designed a retrospective,
longitudinal study to evaluate incidence and predictors of LF
progression, as well as of clinical events and death in a large
cohort of HIV/HCV-coinfected patients with detectable HCV-
RNA and developed clinically comprehensive models for
predicting both LF progression and death in these patients.2. Methods
2.1. Selection of patients
The study was conducted within the MASTER (MAnagement
Standardizzato di TErapia antiRetrovirale, Standardized Man-
agement of Antiretroviral Therapy) cohort, a longitudinal
multicenter cohort consisting of a general HIV-infected patient
population in nine referral centers throughout Italy (http://www.
mastercohort.it).[17] The distinguishing characteristic of this
cohort is that real-life data are recorded in a shared electronic
chart (Health & Notes 3.5W, Healthware S.p.A., Naples, Italy)
used in the participating centers. Data are recorded over a
standardized time scale every 3/6 months, with merging and data
cleaning performed at the coordinating center every 6 months.[17]
The electronic database is used tomanage everyday activity of the
outpatient HIV clinics in each center. The resulting cohort is
therefore an open cohort in which patients are enrolled without
preselection. Subjects gave written informed consent for
participation in the observational cohort, and each site obtained
approval by its ethics committee.
Within this cohort, we performed a retrospective study of HIV-
infected patients with HCV coinfection, deﬁned as positive HCV-
Ab and detectable HCV-RNA. Patients aged 18 years or more,
naïve to antiretroviral therapy at the time of enrollment in the
cohort (from January 1989 to December 2014), with at least 2
available FIB-4 results obtained 3 months apart prior to starting
cART were included. Exclusion criteria were as follows: HBsAg
positivity, reported actual or past alcohol abuse, previous anti-
HCV treatment with interferon± ribavirin, diagnosis of cirrhosis
or hepatocellular carcinoma (HCC) and baseline advanced LF
according to FIB-4 index (baseline FIB-4 class 3, see below).2.2. Assessment of liver ﬁbrosis
LF was estimated using FIB-4 score, calculated using Sterling
formula,[13] as follows: age [years]AST [IU/L]/platelet count
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described,[16] LF was ranked using standard cut-off values into 3
classes corresponding to increased severity of LF: FIB-4 class 1,
1.45 (no clinically signiﬁcant ﬁbrosis); FIB-4 class 2, from 1.46
through 3.25 (moderate ﬁbrosis); FIB-4 class 3, >3.25 (signiﬁ-
cant ﬁbrosis or cirrhosis).2.3. Follow-up and study outcomes
Patients were followed from baseline (date of ﬁrst available FIB-4
result conﬁrmed in the same class at least 3 months apart) to the
time of death, outcome occurrence (see below) or to the last
available visit. Follow-up was also interrupted in the case of
incident HBsAg positivity, diagnosis of HCC, prescription of
anti-HCV treatment or spontaneous HCV-RNA clearance, and
when patient were lost to study follow-up.
The 4 outcomes of the study were as follows: composite
outcome, deﬁned as death or the occurrence of at least one of the
following clinical events, liver-related disease, cardiovascular
event, kidney-related disease, neurological event, or AIDS-
deﬁning event, classiﬁed as presented in a recent MASTER
cohort study[18]; transition from baseline FIB-4 class to any
higher class during the follow-up period (i.e., from class 1 to class
2 or 3; or from class 2 to class 3); transition from baseline FIB-4
class 1 or 2 to FIB-4 class 3 during the follow-up period; increase
of FIB-4 score more than half a point from baseline.
Owing to the fact that these scores may ﬂuctuate or revert back
to lower classes after initial worsening, FIB-4 class transition was
deﬁned in our analyses as a transition to higher classes conﬁrmed
in 2 subsequent measurements at least 3 months apart (unless
follow-upwas truncated). Right censoring of follow-up times was
employed for all outcomes, namely end of follow-up for outcome
1, and end of follow-up, death, HCC, start of interferon therapy,
HCV-RNA clearance.2.4. Data collection
Baseline data included date of birth, gender, ethnicity, date of ﬁrst
HIV diagnosis, risk factors for HIV acquisition, CDC stage, nadir
CD4+ T cell count. The following parameters were collected at
baseline and every 3 to 6 months: antiretroviral regimens
prescribed (categorized as: naïve; ritonavir boosted protease
inhibitors [PI/r]-based; protease inhibitors [PI]-based; nucleoside
reverse transcriptase inhibitors [NRTI] or nonnucleoside reverse
transcriptase inhibitors [NNRTI]-based regimens, or other
regimens; treatment interruption), CD4+ T-cell and CD8+ T-
cell counts, HIV-RNA, AST, ALT, total bilirubin, g-glutamyl
transferase (gGT) level (as a surrogate marker of alcohol intake,
even not reported by the patient)[19] and platelet count. FIB-4
index was calculated at baseline and during follow-up using data
collected at each time point.2.5. Statistical analysis
Continuous variables were described by median and interquartile
range (IQR), while categorical variables were described by
frequencies. Study outcomes were evaluated in terms of incidence
and prevalence with Poisson conﬁdence intervals. Survival
probability estimates at various time points, as well as crude
hazards were assessed via Kaplan–Meier analysis. Multivariate
survival analysis was performed using Cox regression for all
outcomes, with the inclusion of time-updated covariates.3A 2-tailed P-value of <0.05 was considered statistically
signiﬁcant. All analyses were performed using the R language for
statistical computing (https://www.r-project.org/).3. Results
3.1. Population characteristics
A total of 1433 HIV positive patients coinfected with HCV
fulﬁlled the inclusion criteria and were included in the analysis.
Baseline population characteristics are summarized in Table 1.
Most patients were males, predominantly young (median age was
34 years) and acquired HIV infection through intravenous drug
use. According to FIB-4, baseline LF was classiﬁed as class 1 or 2
in 70.41% and 29.59% of patients, respectively.3.2. Incidence of clinical outcomes and liver ﬁbrosis
progression according to FIB-4
A total of 745 clinical events or deaths occurred overall (Fig. 1A),
with an incidence of 7.6% (95% conﬁdence interval [CI]:
7.1%–8.2%) over 9811 PYFU and a median survival of 9.36
(95% CI: 7.64–10.1) years. A total of 525 liver-related events
occurred in patients without these events at baseline (with an
incidence of 4% over 11,671 PYFU and a median survival of
18.73 years). All the events contributing to the composite
outcome including causes of death are shown in Table 1. The
composite outcome counts only the ﬁrst qualifying event if more
than 1 happen over time (745 over a total of 1020); on the liver
event outcome, liver events were not considered after occurrence
of censoring conditions (HCC/interferon/HCV clearance).
As shown in Fig. 1B, incidence of LF progression from FIB-4
class 1 to class 2 or 3 was 12.4% (95% CI: 11.7–13.2),
accounting for 1107 events with a median survival time of 5.67
years (95% CI: 5.17–6.16) over 8913 PYFU. Incidence of LF
progression from FIB-4 class 2 to 3 (Fig. 1C) was 7% (95% CI:
6.3–7.8); we recorded 365 events over 5191 PYFUwith a median
survival time of 10.35 years (95% CI: 9.36–11.33). Lastly, FIB-4
increase of at least half a point from baseline was observed in
1644 cases with an incidence of 12.6% (95% CI: 12–13.2) over
13,079 PYFU and an estimated median survival time of 5.91
years (95% CI: 5.42–6.16) (see Fig. 1D).3.3. Predictors of death, clinical, and liver ﬁbrosis
progression according to FIB-4
Predictors of the 4 outcomes were investigated using multivariate
Cox regression analysis with both time-ﬁxed (collected at
baseline) and time-updated (collected at baseline and during
follow up) variables (detailed results of the multivariable analysis
are reported in the Supplementary Material, http://links.lww.
com/MD/B121 and depicted in Fig. 2).
At multivariate analysis, intravenous drug use (as a risk factor
for HIV acquisition) and current gGT increase (as time-
dependent variable) were signiﬁcant risk factors for any
outcomes. Indeed, relative hazard ratios (HR) ranged from
0.76 (95% CI: 0.58–1; P=0.0460) for intravenous drug use for
transition of FIB-4 from class 2 to class 3 to 0.84 (95% CI:
0.70–1; P=0.05) for intravenous drug use for the composite
clinical outcome. Also, an increased current gGT (per Log higher)
increased the risk of composite clinical events (HR 1.16, 95%CI:
1.08–1.26; P=0.0001) and the risk of transition of FIB-4 from
class 2 to class 3 (HR 1.76, 95% CI: 1.57–1.96; P<0.0001).
Table 1
Baseline characteristics of patients.
Variable All patients (1433)
Age, y (median, IQR) 34 (30–39)
Gender (n, %)
Male 1066 (74.39)
Female 367 (25.61)
Risk factor for HIV acquisition (n, %)
Heterosexual 201 (14.03)
Homo/bisexual 89 (6.21)
IDU 1016 (70.89)
Other/unknown 127 (8.87)
Follow-up, y (median, IQR) 5.4 (2.2–10.1)
CD4+ T-cell count (median, IQR) 292 (171–426)
HIV-RNA log10 (median, IQR) 4.06 (1.94–4.89)
HCV-RNA log10 (median, IQR) 5.84 (5.26–6.31)
FIB-4 score (n, %)
Class 1 1009 (70.41)
Class 2 424 (29.59)
FIB-4 score (median, IQR) 1.09 (0.78–1.54)
gGT, IU (median, IQR) 130.9 (89–130.9)
Events observed (including causes of death) All events (1020)
N (%)
Liver disease 545 (38.03)
Kidney disease 244 (17.03)
Cardiovascular disease 84 (5.86)
Neurologic disease 49 (3.42)
AIDS-deﬁning events 98 (6.84)
Death
AIDS 13 (0.91)
Liver related 22 (1.54)
Cardiovascular related 5 (0.35)
Other/unknown 32 (2.23)
gGT=gamma-glutamyl transpeptidase, IDU= injecting drug users, IQR= interquartile range, IU=
international unit.
Focà et al. Medicine (2016) 95:29 MedicineHigher CD4+ T-cell count during follow-up predicted a lower
risk of clinical events and deaths (composite outcome), while both
lower HIV-RNA and higher CD4+ T-cell count appeared to
protect from FIB-4 transitions (both for progression to class 2 or
3 and for the ≥0.5 point increase). For example, with respect to
FIB-4 transition from class 2 to class 3, increased HIV-RNA (per
Log higher) accounted for a HR of 1.42 (95%CI: 1.30–1.54; P<
0.0001).
Occurrence of AIDS-deﬁning events predicted ≥0.5 point
increase in FIB-4 (HR 1.39, 95% CI: 1.19–1.61; P<0.0001),
while kidney events were signiﬁcant risk factors for both
transition from class 2 to class 3 (HR 1.82, 95% CI:
1.09–3.03; P=0.0221) and ≥0.5 point increase in FIB-4 (HR
1.35, 95% CI: 1.06–1.72; P=0.0156). Conversely, we observed
that FIB-4 class 3 (time updated) was a predictor of the composite
outcome (any clinical events and death), independently from the
other variables tested (HR 1.64 vs class 1, 95% CI: 1.23–2.19;
P=0.0008). Lastly, we found that time-updated FIB-4 was a
signiﬁcant predictor of liver-related events independently from
other factors (hazard ratio, HR: 1.33, 95% CI: 1.10–1.62; P=
0.0038 for FIB-4 class 2 vs 1, and HR: 2.40, 95% CI: 1.75–3.30;
P<0.0001 for FIB-4 class 3 vs 1).
From analyzing the impact of antiretroviral therapy on LF
progression, a prolonged exposure to NRTIs appeared to be a
consistent predictor for FIB-4 evolution. For example, prolonging
exposure by one year accounted for a HR of 1.10 (95% CI:
1.03–1.18; P=0.0077) for FIB-4 transition from class 2 to class43. For other drug classes, results were less consistent, with
NNRTI protecting from transition to class 2 or 3, and use of
single PI (but not boosted by ritonavir) promoting ≥0.5 point
increase of FIB-4. Use of NNRTI and of PI/r (but not the use of
unboosted PI) displayed a protective effect for the composite
clinical outcome: for NNRTI, the HR was 0.92 (95% CI:
0.86–0.97; P=0.0043) and for boosted PI regimens the HR was
0.85 (95% CI: 0.77–0.93; P=0.0004).4. Discussion
This study evaluated incidence and predictors of LF progression
(estimated by FIB-4 index) and outcomes of HIV/HCV-
coinfected patients included in the Italian MASTER cohort.
We feel that our ﬁndings are innovative and applicable to clinical
practice.
Most importantly, we found that incidence rate of LF
progression in HIV/HCV-coinfected patients is far higher than
that estimated in HIV mono-infected patients belonging to the
same cohort.[13] For instance, the incidence of transition to FIB-4
>3.25 was 0.013 per PYFU in our previous analysis[13] vs 0.070
per PYFU in the present study. Therefore, although patients seem
to be protected by cART especially in the ﬁrst years after its
prescription (as recently suggested by prospective data in a small
patient cohort),[20] LF progressed faster afterwards, making HIV/
HCV-coinfected patients a population that should be prioritized
for access to HCV treatment. Unfortunately, the high cost of the
new directly acting antivirals limits the applicability of such
therapy in many countries, such as in Italy. For this reason, it is
still important to deﬁne the best predictors of LF progression to
address drug prescription to the most-at-risk patients.
A strong association between higher baseline FIB-4 and LF
progression was observed. This may indicate that patients with
higher degrees of LF should be considered a high priority group
for anti-HCV therapy. Also, we were able to identify other
predictors of LF progression, which may help to individualize
drug prescription and intensity of clinical monitoring.
Current or past intravenous drug use appeared to predict LF
progression and death or clinical events (composite outcome). So,
this group of patients should be strictly monitored for LF
progression and anti-HCV treatment should be proposed earlier
if not contraindicated.
As in HIV mono-infected patients,[13] abnormal gGT levels
were associated with faster transition to higher FIB-4 classes,
possibly related to undisclosed alcohol consumption. However,
other factors could have contributed to this ﬁnding such as liver
toxicity due to comedications or some antiretroviral drugs. On
the other hand, increased levels of gGT predicted death or clinical
events at the composite outcome, which is likely due to the
severity of liver disease and liver-related complications.
We found that AIDS-deﬁning and kidney-related events were
signiﬁcant predictors of ≥0.5 point worsening in FIB-4, while
clinical events (in particular kidney related) increased the risk of
transitions to FIB-4 class 3. Clearly, worsening of liver function
may accompany or lead to several clinical problems including not
only liver-related events, but also neurological, cardiovascular,
kidney-related, and AIDS-deﬁning events. The role of these
clinical events for prediction of LF progression is somewhat
unexpected and not well explained. However, Lapadula[18]
previously demonstrated in our cohort that patients who
experienced previous AIDS-deﬁning events were more at risk
for non-AIDS-deﬁning events, so these factors appear to be
intertwined.
Figure 1. Incidence of clinical outcome and liver ﬁbrosis progression according to FIB-4: (A) composite event (clinical events and death); (B) FIB-4 increase from
class 1 to class 2/3; (C) FIB-4 increase from class 2 to 3; (D) FIB-4 increase of half a point from baseline.
Focà et al. Medicine (2016) 95:29 www.md-journal.comConsistent with this hypothesis, better immune recovery
appeared to reduce the overall disease progression in HIV/
HCV-coinfected patients both in terms of clinical events and LF
in the present study. In fact, although only higher CD4+ T-cell
count protected from death and composite outcome, both higher
CD4+ T-cell count and lower HIV-RNA seemed to protect from
worsening of LF. These ﬁndings were previously demonstrated
both in HIV mono-infected patients and in HCV-coinfected
patients.[15,20–23] Our data conﬁrm that viro-immunological
parameters may have a role in LF progression. A cross-talk
among HIV and HCV proteins in coinfected patients modulates
the natural history, the immune responses, and the life cycle of
both viruses. These effects are mediated by immune mechanisms
and by cross-talking between the 2 viruses which could interfere
with host defense mechanisms, as recently reviewed by
Liberto.[24] From a clinical point of view, the current data
strongly indicate the need for starting both cART and HCV
therapy as soon as possible.
A lower risk of LF progression was observed in recent calendar
years. This could be ascribed to the shorter follow-up of patients,
but also to earlier initiation of antiviral therapy according to the
recent guidelines[25] or to the better liver tolerability of new
generation of antiretroviral drugs. In fact, in our multivariate5analysis, prolonged exposure to NRTIs predicted LF progression.
A potential explanation could be the potential liver toxicity due
to antiretroviral drugs belonging to this class (particularly
dideoxynucleoside analogs). Indeed, these drugs were associated
with cryptogenic liver disease and microvesicular steatosis.[26,27]
In addition, we found a protective role of both exposure to
NNRTIs and to ritonavir-boosted PIs for the composite outcome.
Moreover, NNRTI exposure appeared to counteract progression
of LF (from class 2 to class 3). These associations could be
explained by the overall advantages of these antiretroviral
regimens on the clinical outcome compared to suboptimal
regimens based on NRTI only.[28] However, the use of these
regimens has been abrogated in the modern cART era. Perhaps
more important is the apparent protective effect of NNRTI
containing regimens, which could be ascribed to better
tolerability and metabolic proﬁle of this kind of therapy.[29]
We hypothesized that containment of insulin resistance and lipid
increase attributed to these regimens may have given some
beneﬁts to the liver of our patients in terms of steatosis, slowing
down progression of LF. Lastly, exposure to unboosted PIs
seemed to promote LF progression (>0.5 point FIB-4 increase).
We are not sure whether this is a true cause–effect ﬁnding or
simply reﬂects the habit to prescribe these antiretroviral regimens
Figure 2. Predictors of death, clinical events, and liver ﬁbrosis progression according to FIB-4. Adjusted for: gender, increased HCV-RNA (per Log higher), other
antiretrovirals cumulative exposure years, neurological events. Variables with P<0.1 for at least 1 outcome are shown. ART=antiretroviral therapy, IDU= injecting
drug users, GGT=gamma-glutamyl transferase, NRTI=nucleos(t)ide reverse transcriptase inhibitors, NNRTI=nonnucleoside reverse transcriptase inhibitors, PI=
protease inhibitors, RTV/b= ritonavir boosted protease inhibitors, CVE=cardiovascular events.
Focà et al. Medicine (2016) 95:29 Medicinein coinfected patients withmore advanced liver disease because of
the perception of better tolerability or pharmacokinetic pro-
ﬁles.[30,31] However, this effect was not conﬁrmed for the other
FIB-4 endpoints, so its clinical meaningfulness is reduced.
Some limitations should be discussed when interpreting the
results of our study. First, LF was monitored using a noninvasive
score, which is not the gold standard for LF assessment.
However, liver biopsy is impractical for serial evaluations and not
applicable in longitudinal cohort studies that require multiple
evaluations of LF. Transient elastography could have been an
alternative tool,[32] but this technique has become available only
in recent years, thus limiting the length of follow-up; moreover,
this tool could not have been applied to such a large population
for practical reasons, and furthermore, elastography may be
affected by operator-based biases. Despite a recent study found
that noninvasive markers are not optimal,[20] these markers were
already validated for estimating LF[13] and predicted hepatic
decompensation and death in cohorts of patients.[4,15] For these
reasons, the European Association for the Study of the Liver
(EASL) provided speciﬁc guidelines for the use of these scores in
clinical practice.[12] Second, in dealing with a possible effect of
antiretroviral drugs, we did not try to disregard the impact of
individual compounds because of the risk of introducing biases
when statistical analysis is “forced” to provide such levels of
details given the fact that combination of drugs are prescribed.
Indeed, we feel that the impact of individual compounds merits to
be addressed in speciﬁc studies, either in patients drug-naïve on
treatment or after switching.
The innovative strength of this study, making it one of the few
in current literature in this ﬁeld, was that we did not include all
HCV-Ab positive patients but only those with detectable HCV-
RNA (i.e., actual HIV/HCV coinfection). Studies that also
included patients who may have spontaneously eradicated HCV
after infections may have underestimated the risk of LF
progression and given less accurate estimates of the risk factors.
Moreover, in this study we performed an extensive risk
assessment evaluating in the same cohort both the impact of
LF on clinical outcomes and predictors of LF with the objective to6suggest possible causal networks and interventions targeted to
factors that come ﬁrst in the pathway of events. Moreover, to
provide clinicians with an overall picture of risk factors, we have
performed multivariate analyses for each outcome.
In conclusion, patients with advanced viro-immunological
status, with identiﬁcation as intravenous drug users andwith high
gGT are most-at-risk for LF progression and clinical complica-
tions of HIV disease, especially if heavily exposed to the NRTI
class of antiretroviral drugs. Importantly, FIB-4 evaluated at
baseline and during therapy is an independent predictor of these
clinical complications. The complex network of LF and clinical
evaluation in patients coinfected by HIV and HCV should be
taken into account as they should provoke further pathogenetic
and clinical investigations for optimal clinical management. In
particular, test-and-treat strategies (leading to both earlier cART
and earlier treatment for HCV) should be urgently implemented.Acknowledgments
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